Grayscale lobbies SEC to approve options products based on physically settled Bitcoin ETF
Cryptocurrency asset management company Grayscale Investments wrote to the US SEC lobbying for approval of options products based on a spot Bitcoin ETF. Grayscale CEO Michael Sonnenshein stated in the letter to the SEC that the rejection of options for its Grayscale Bitcoin Trust (GBTC.P) would "unfairly discriminate" against its shareholders, pointing out that regulatory agencies had previously approved options related to Bitcoin futures ETFs. Sonnenshein mentioned that options would facilitate price discovery for new ETF shares, aiding investors in navigating market conditions, hedging, and generating income. Furthermore, options would also "allow more regulated market participants" (such as contract traders and broker-dealers) to trade products, further bringing Bitcoin into regulatory oversight.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
